Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

• Main Authors: Navita L. Mallalieu (Author), Sunethra Wimalasundera (Author), Joy C. Hsu (Author), Wendy Douglass (Author), Chris Wells (Author), Inmaculada Calvo Penades (Author), Ruben Cuttica (Author), Hans-Iko Huppertz (Author), Rik Joos (Author), Yukiko Kimura (Author), Diana Milojevic (Author), Margalit Rosenkranz (Author), Kenneth Schikler (Author), Tamas Constantin (Author), Carine Wouters (Author)
• Format: Book
• Published: BMC, 2019-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background The anti-interleukin-6 receptor-alpha antibody tocilizumab was approved for intravenous (IV) injection in the treatment of patients with systemic juvenile idiopathic arthritis (sJIA) aged 2 to 17 years based on results of a randomized controlled phase 3 trial. Tocilizumab treatme...